320 related articles for article (PubMed ID: 32719267)
1. Metronomic palliative chemotherapy in locally advanced, recurrent and metastatic head-and-neck cancer: A single-arm, retrospective study of a regional cancer center of North India (Asia).
Harsh KK; Maharia SR; Nirban RK; Khatri P; Beniwal S; Kumar HS; Jakhar SL
J Cancer Res Ther; 2020; 16(3):559-564. PubMed ID: 32719267
[TBL] [Abstract][Full Text] [Related]
2. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.
Patil V; Noronha V; Dhumal SB; Joshi A; Menon N; Bhattacharjee A; Kulkarni S; Ankathi SK; Mahajan A; Sable N; Nawale K; Bhelekar A; Mukadam S; Chandrasekharan A; Das S; Vallathol D; D'Souza H; Kumar A; Agrawal A; Khaddar S; Rathnasamy N; Shenoy R; Kashyap L; Rai RK; Abraham G; Saha S; Majumdar S; Karuvandan N; Simha V; Babu V; Elamarthi P; Rajpurohit A; Kumar KAP; Srikanth A; Ravind R; Banavali S; Prabhash K
Lancet Glob Health; 2020 Sep; 8(9):e1213-e1222. PubMed ID: 32827483
[TBL] [Abstract][Full Text] [Related]
3. Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study.
Harsh KK; Jakhar SL; Maheshwari G; Nirban R; Kumari P; Beniwal SK; Sharma N; Kumar HS
Indian J Cancer; 2023; 60(2):167-172. PubMed ID: 37530237
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of Head and Neck Cancer Patients Treated with Palliative Oral Metronomic Chemotherapy at a Tertiary Cancer Center in Kerala, India.
Nv V; Muttath G; Jones J; Shringarpure K; Duraisamy K; Deenathayalan VP; Rathi P
Gulf J Oncolog; 2020 May; 1(33):68-74. PubMed ID: 32476653
[TBL] [Abstract][Full Text] [Related]
5. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.
Patil VM; Chakraborty S; Jithin TK; Sajith Babu TP; Babu S; Kumar S; Biji MS; Bhattacharjee A; Balasubramanian S
South Asian J Cancer; 2016; 5(2):48-51. PubMed ID: 27275445
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K
Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869
[TBL] [Abstract][Full Text] [Related]
7. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.
Patil VM; Noronha V; Joshi A; Dhumal S; Mahimkar M; Bhattacharjee A; Gota V; Pandey M; Menon N; Mahajan A; Sable N; Kumar S; Nawale K; Mukadam S; Solanki B; Das S; Simha V; Abraham G; Chandrasekharan A; Talreja V; DSouza H; Srinivas S; Kashyap L; Banavali S; Prabhash K
J Clin Oncol; 2019 Nov; 37(32):3032-3041. PubMed ID: 31539316
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
10. Metronomic chemotherapy in advanced oral cancers.
Patil V; Noronha V; D'cruz AK; Banavali SD; Prabhash K
J Cancer Res Ther; 2012 Jan; 8 Suppl 1():S106-10. PubMed ID: 22322727
[TBL] [Abstract][Full Text] [Related]
11. Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.
Guo Y; Ahn MJ; Chan A; Wang CH; Kang JH; Kim SB; Bello M; Arora RS; Zhang Q; He X; Li P; Dechaphunkul A; Kumar V; Kamble K; Li W; Kandil A; Cohen EEW; Geng Y; Zografos E; Tang PZ
Ann Oncol; 2019 Nov; 30(11):1831-1839. PubMed ID: 31501887
[TBL] [Abstract][Full Text] [Related]
12. Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
Grünwald V; Chirovsky D; Cheung WY; Bertolini F; Ahn MJ; Yang MH; Castro G; Berrocal A; Sjoquist K; Kuyas H; Auclair V; Guillaume X; Joo S; Shah R; Harrington K;
Oral Oncol; 2020 Mar; 102():104526. PubMed ID: 31978755
[TBL] [Abstract][Full Text] [Related]
13. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
15. Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.
Patil V; Noronha V; Krishna V; Joshi A; Prabhash K
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):388. PubMed ID: 23434353
[No Abstract] [Full Text] [Related]
16. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
17. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
18. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
[TBL] [Abstract][Full Text] [Related]
19. A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Kochanny SE; Worden FP; Adkins DR; Lim DW; Bauman JE; Wagner SA; Brisson RJ; Karrison TG; Stadler WM; Vokes EE; Seiwert TY
Cancer; 2020 May; 126(10):2146-2152. PubMed ID: 32073648
[TBL] [Abstract][Full Text] [Related]
20. Comparison of paclitaxel-cetuximab chemotherapy versus metronomic chemotherapy consisting of methotrexate and celecoxib as palliative chemotherapy in head and neck cancers.
Patil VM; Noronha V; Joshi A; Agarwala V; Muddu V; Ramaswamy A; Chandrasekharan A; Dhumal S; Juvekar S; Arya A; Bhattacharjee A; Prabhash K
Indian J Cancer; 2017; 54(1):20-24. PubMed ID: 29199655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
